Elvitegravir: a once daily alternative to raltegravir.

摘要

Combination antiretroviral treatment has transformed HIV infection from a deadly disease to a chronic one. Long-term suppression of viraemia requires patients' commitment to take antiretroviral drugs on a daily basis for the rest of their lives. Although more than 25 antiretroviral drugs have been approved for clinical use, novel and better treatment options are needed for individuals in whom existing regimens fail because of antiviral resistance or side-effects.HIV integrase inhibitors are potent antivirals that induce a rapid and durable decrease in viral load. Raltegravir and elvitegravir are members of this class of drug. Regimens based on a twice-daily dose of raltegravir are recommended for management of both treatment-experienced and treatment-naive HIV-infected patients; once-daily dosing of raltegravir is not recommended. Elvitegravir is an investigational drug that is suitable for once-daily dosing when combined with a pharmacokinetic booster.